JANX Janux Therapeutics
- 47.480
- -0.430-0.90%
- 48.260
- +0.780+1.64%
Janux Therapeutics News
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Janux Therapeutics (JANX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $50.00 to $63.00.
HC Wainwright & Co. : Maintaining the Janux Therapeutics (JANX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $50.00 to $63.00.
HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $63
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $50 to $63.
Buy Rating Affirmed for Janux Therapeutics With Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Inc.: The Janux Therapeutics (JANX.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $100.00.
Cantor Fitzgerald Inc.: The Janux Therapeutics (JANX.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $100.00.
Cantor Fitzgerald Reiterates Overweight on Janux Therapeutics, Maintains $100 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Janux Therapeutics with a Overweight and maintains $100 price target.
We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
Janux Therapeutics: Promising Early Data for EGFR-Targeted Therapies Warrants a Buy Rating
Insiders Made Right Decision To Sell As Janux Therapeutics Dips 11%
Insiders seem to have made the most of their holdings by selling US$1.3m worth of Janux Therapeutics, Inc. (NASDAQ:JANX) stock at an average sell price of US$45.94 during the past year. The company's
Janux Therapeutics | 10-Q: Quarterly report
Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Janux Therapeutics Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Janux Therapeutics Is Maintained at Outperform by Wedbush
Janux Therapeutics Is Maintained at Outperform by Wedbush
Janux Therapeutics Price Target Raised to $74.00/Share From $53.00 by Wedbush
Janux Therapeutics Price Target Raised to $74.00/Share From $53.00 by Wedbush
Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $74
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $53 to $74.
Janux Therapeutics Inc Files For Mixed Shelf; Sales Agreement Prospectus Covers Offering Of Up To $150M Of Common Stock That May Be Issued And Sold From Time To Time
Janux Therapeutics Inc Files For Mixed Shelf; Sales Agreement Prospectus Covers Offering Of Up To $150M Of Common Stock That May Be Issued And Sold From Time To Time
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating
Janux Therapeutics (JANX) has an average rating of buy and price targets ranging from $25 to $100, according to analysts polled by Capital IQ. Price: 63.62, Change: +2.12, Percent Change: +3.45
Janux Therapeutics Inc (JANX) Gets a Buy From Wedbush
Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates
Analysis
Price Target
No Data
